SCA
LGND icon

Snowden Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Snowden Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
+760
New +$179K 0.01% 1197
2022
Q1 		– Sell
-83
Closed -$8K – 1618
2021
Q4 		$8K Buy
+83
New +$7.67K ﹤0.01% 1583

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Snowden Capital Advisors's LGND Position: Q2 2026 in Review

Snowden Capital Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 760 shares worth $240K. The stake represents 0.01% of the portfolio and ranks #1197 among its holdings. This is a return to the name: Snowden Capital Advisors previously reported a position in LGND as recently as Q4 2021.

Snowden Capital Advisors first reported a position in LGND in Q4 2021 and has held it in 2 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Snowden Capital Advisors held 760 shares of Ligand Pharmaceuticals worth $240K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Snowden Capital Advisors position in Q2 2026.
  • Ligand Pharmaceuticals made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1197 holding.
  • Snowden Capital Advisors first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.